A randomized controlled pilot study of add-on therapy of CIM-MEG19 (standardized formulation) in mild to moderate COVID-19.

Background: Traditional knowledge and scientific shreds of evidence strongly support the repurpose of Kalmegh (, CIM-MEG19) as an alternate therapy for prophylactic management and treatment of severe acute respiratory syndrome coronavirus (SARS-CoV) and associated health disorders.

Purpose: The study aimed to assess the efficacy and safety of the CIM-MEG19 (standardized extract formulation), a proprietary medicine in the COVID-19 management, clinical recovery, and outcomes in terms of hospitalization days as well as any sign of severity due to drug-drug interaction between CIM-MEG19 and standard of care (SoC).

Methods: A randomized, parallel-group, active-controlled interventional pilot clinical study was conducted.